In conclusion, CPIT with n-IFN-β as IT followed by triple therapy with PI plus PR is more effective for the treatment of difficult-to-treat CHC patients with genotype 1b and high viral loads than IT with nIFN-β followed by PR alone. The gene discussed is IFNB1; the disease is cryohydrocytosis.